SinuSonic for Facial Pain

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Mayo Clinic Arizona, Phoenix, AZ
Facial Pain+1 More
SinuSonic - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to investigate if the SinuSonic device decreases facial pain and pressure compared to the placebo device.

Eligible Conditions

  • Facial Pain

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 3 Secondary · Reporting Duration: 8 weeks

8 weeks
Subjects reporting epistaxis
Subjects reporting pain with device use
Baseline, 8 weeks
Change in Brief Pain Inventory Short Form
Change in facial pain
Change in nasal obstruction symptoms

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

SinuSonic Group
1 of 2
Sham Group
1 of 2
Experimental Treatment
Non-Treatment Group

99 Total Participants · 2 Treatment Groups

Primary Treatment: SinuSonic · Has Placebo Group · N/A

SinuSonic Group
Device
Experimental Group · 1 Intervention: SinuSonic · Intervention Types: Device
Sham Group
Device
ShamComparator Group · 1 Intervention: Sham Device · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 8 weeks
Closest Location: Mayo Clinic Arizona · Phoenix, AZ
Photo of mayo clinic arizona 1Photo of mayo clinic arizona 2Photo of mayo clinic arizona 3
2005First Recorded Clinical Trial
1 TrialsResearching Facial Pain
150 CompletedClinical Trials

Who is running the clinical trial?

Mayo ClinicLead Sponsor
2,860 Previous Clinical Trials
3,686,062 Total Patients Enrolled
1 Trials studying Facial Pain
300 Patients Enrolled for Facial Pain
Amar Miglani, MDPrincipal InvestigatorMayo Clinic

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are not overtly unhealthy as determined by medical evaluation.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.